SOURCE: Targeted Genetics

March 26, 2007 07:30 ET

Targeted Genetics to Present at the Future Leaders in the Biotech Industry Investor Conference

SEATTLE, WA -- (MARKET WIRE) -- March 26, 2007 -- Targeted Genetics Corporation (NASDAQ: TGEN) announced today that H. Stewart Parker, president and chief executive officer, will provide an overview of the Company's product development programs and business strategy at the Future Leaders in the Biotech Industry Investor Conference in New York on Thursday, March 29, 2007 at 11:30 a.m. (ET).

The presentation will be webcast live and available for replay from the Targeted Genetics website, The link to connect is on the Company's homepage under the "Events" section.

About Targeted Genetics

Targeted Genetics Corporation is a biotechnology company committed to the development of innovative targeted molecular therapies for the prevention and treatment of acquired and inherited diseases with significant unmet medical need. Targeted Genetics' proprietary Adeno-Associated Virus (AAV) technology platform allows it to deliver genes that encode proteins to increase gene function or RNAi to decrease or silence gene function. Targeted Genetics' product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure and Huntington's disease. To learn more about Targeted Genetics, visit Targeted Genetics' website at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements regarding our intent to present an overview of the Company's clinical and business developments at a conference. These statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect these statements include, but are not limited to, our ability to raise capital when needed, the timing, enrollment of patients, nature and results of our clinical trials, potential development of alternative technologies or more effective products by competitors, our ability to obtain and maintain regulatory or institutional approvals, and our ability to obtain, maintain and protect our intellectual property, as well as other risk factors described in Item 1A. Risk Factors in our reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

Contact Information

  • Investor and Media Contact:
    Stacie D. Byars
    Director, Communications
    Targeted Genetics Corporation
    (206) 521-7392